<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Parkinsons Dis</journal-id><journal-title-group><journal-title>NPJ Parkinson's Disease</journal-title></journal-title-group><issn pub-type="epub">2373-8057</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7441399</article-id><article-id pub-id-type="publisher-id">123</article-id><article-id pub-id-type="doi">10.1038/s41531-020-00123-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>COVID-19 and possible links with Parkinson&#x02019;s disease and parkinsonism: from bench to bedside</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7632-0439</contrib-id><name><surname>Sulzer</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1040-2807</contrib-id><name><surname>Antonini</surname><given-names>Angelo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Leta</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Nordvig</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Smeyne</surname><given-names>Richard J.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Goldman</surname><given-names>James E.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Al-Dalahmah</surname><given-names>Osama</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Zecca</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Sette</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7927-9208</contrib-id><name><surname>Bubacco</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8333-4804</contrib-id><name><surname>Meucci</surname><given-names>Olimpia</given-names></name><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Moro</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff16">16</xref><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7054-2812</contrib-id><name><surname>Harms</surname><given-names>Ashley S.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yaqian</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Fahn</surname><given-names>Stanley</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2815-0505</contrib-id><name><surname>Ray Chaudhuri</surname><given-names>K.</given-names></name><address><email>ray.chaudhuri@kcl.ac.uk</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label>Departments of Psychiatry, Neurology, Pharmacology, Columbia University Medical Center, New York State Psychiatric Institute, New York, NY 10032 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5608.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 3470</institution-id><institution>Department of Neuroscience, Parkinson and Movement Disorders Unit, </institution><institution>University of Padua, </institution></institution-wrap>Padua, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution>King&#x02019;s College London, Institute of Psychiatry, Psychology &#x00026; Neuroscience, </institution></institution-wrap>De Crespigny Park, London, SE5 8AF UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.46699.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0391 9020</institution-id><institution>Parkinson&#x02019;s Foundation Centre of Excellence, </institution><institution>King&#x02019;s College Hospital, </institution></institution-wrap>Denmark Hill, London, SE5 9RS UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.21729.3f</institution-id><institution-id institution-id-type="ISNI">0000000419368729</institution-id><institution>Department of Neurology, Vagelos College of Physicians and Surgeons, </institution><institution>Columbia University and the New York Presbyterian Hospital, </institution></institution-wrap>New York, NY 10032 USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.265008.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2166 5843</institution-id><institution>Department of Neurosciences, </institution><institution>Thomas Jefferson University, </institution></institution-wrap>Philadelphia, PA 19107 USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.21729.3f</institution-id><institution-id institution-id-type="ISNI">0000000419368729</institution-id><institution>Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, </institution><institution>Columbia University and the New York Presbyterian Hospital, </institution></institution-wrap>New York, NY 10032 USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.5326.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 1940 4177</institution-id><institution>Institute of Biomedical Technologies, </institution><institution>National Research Council of Italy, </institution></institution-wrap>Segrate, Milan, Italy </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.185006.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0461 3162</institution-id><institution>Division of Vaccine Discovery, </institution><institution>La Jolla Institute for Allergy and Immunology, </institution></institution-wrap>La Jolla, CA 92093 USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Department of Medicine, </institution><institution>University of California, </institution></institution-wrap>San Diego, CA 92093 USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.5608.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 3470</institution-id><institution>Department of Biology, </institution><institution>University of Padova, </institution></institution-wrap>Padova, Italy </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.166341.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 3113</institution-id><institution>Department of Pharmacology and Physiology, </institution><institution>Drexel University College of Medicine, </institution></institution-wrap>Philadelphia, PA 19102 USA </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.166341.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 3113</institution-id><institution>Center of Neuroimmunology and CNS Therapeutics, Institute of Molecular Medicine and Infectious Diseases, </institution><institution>Drexel University College of Medicine, </institution></institution-wrap>Philadelphia, PA 19102 USA </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.166341.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 3113</institution-id><institution>Department of Microbiology and Immunology, </institution><institution>Drexel University College of Medicine, </institution></institution-wrap>Philadelphia, PA 19102 USA </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.410529.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0792 4829</institution-id><institution>Department of Neurology, </institution><institution>Grenoble Alpes University Hospital, </institution></institution-wrap>Grenoble, France </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.462307.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0429 3736</institution-id><institution>Grenoble Institute of Neurosciences GIN-INSERM U1216/CEA/UGA, </institution></institution-wrap>Grenoble, France </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.450307.5</institution-id><institution>Grenoble Alpes University, </institution></institution-wrap>Grenoble, France </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution-id institution-id-type="ISNI">0000000106344187</institution-id><institution>Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, </institution><institution>University of Alabama at Birmingham, </institution></institution-wrap>Birmingham, AL 35294 USA </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.21729.3f</institution-id><institution-id institution-id-type="ISNI">0000000419368729</institution-id><institution>Department of Psychiatry, </institution><institution>Columbia University Irving Medical Center, </institution></institution-wrap>New York, NY 10032 USA </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>6</volume><elocation-id>18</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus on Parkinson&#x02019;s disease. Major points include that neuropathology studies have not answered the central issue of whether the virus enters central nervous system neurons, astrocytes or microglia, and the brain vascular cell types that express virus have not yet been identified. Currently, there is no clear evidence for human neuronal or astrocyte expression of angiotensin-converting enzyme 2 (ACE2), the major receptor for viral entry, but ACE2 expression may be activated by inflammation, and a comparison of healthy and infected brains is important. In contrast to the 1918 influenza pandemic and avian flu, reports of encephalopathy in COVID-19 have been slow to emerge, and there are so far no documented reports of parkinsonism apart from a single case report. We recommend consensus guidelines for the clinical treatment of Parkinson&#x02019;s patients with COVID-19. While a role for the virus in causing or exacerbating Parkinson&#x02019;s disease appears unlikely at this time, aggravation of specific motor and non-motor symptoms has been reported, and it will be important to monitor subjects after recovery, particularly for those with persisting hyposmia.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Translational research</kwd><kwd>Translational research</kwd><kwd>Translational research</kwd><kwd>Translational research</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Over the past twenty years, novel viral epidemics, including influenza, severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS), have appeared, likely through zoonosis<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref></sup>. There are few, if any, therapeutic options for treating these disorders and they can induce significant mortality<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. In 2019, a novel coronavirus outbreak, known as COVID-19, was reported in China, and as of May 2020, it had spread to 229 countries<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par3">This coronavirus, known as SARS-CoV-2, is a large enveloped non&#x02010;segmented positive&#x02010;sense RNA virus<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. When the SARS-CoV-2 virus, and in particular its Spike (S) protein, makes contact with cells, it binds to a number of host proteins (known as virus receptors) that assist in its entry<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>.</p></sec><sec id="Sec2"><title>Symptoms</title><p id="Par4">Like its related family members SARS-CoV and MERS-CoV, SARS-CoV-2 initially presents as a respiratory illness, characterized by cough, dyspnea, fever, and other upper and lower respiratory systems manifestations<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. However, COVID-19 is associated with a variety of other symptoms and clinical manifestations due to its spread to many other organs and systems<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par5">At this time, it appears that all subjects who have recovered from COVID-19 have developed T cells that recognize specific viral epitopes, including the S protein<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. The extraordinarily wide range of symptoms and severity, including many infected subjects showing mild or no effects, may be due to cross-reactivity of T cells previously developed in response to prior coronavirus infections that cross-react with SARS-CoV-2, and it is remarkable that nearly half of individuals tested from blood samples prior to 2019 have such cells<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. It is also possible that different routes of infection, including via the gastrointestinal tract, may result in different symptoms<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par6">Epidemiological and public health studies indicate that infection with the SARS-CoV-2 affects all demographics, but has grave implications for older frail subjects<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, particularly those with comorbidities as well as Black, Asian, and minority ethnic (BAME) subjects in a disproportionate manner (<ext-link ext-link-type="uri" xlink:href="https://www.england.nhs.uk/coronavirus/workforce/addressing-impact-of-covid-19-on-bame-staff-in-the-nhs/">https://www.england.nhs.uk/coronavirus/workforce/addressing-impact-of-covid-19-on-bame-staff-in-the-nhs/</ext-link>). This is not always the case for viral disorders, as some, like polio, are typically more dangerous for the young<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. The impression that SARS-CoV-2 infection was particularly pathogenic in older frail subjects has been confirmed by high mortality rates, particularly in residential home patients across the United Kingdom, Italy, the United States, and many other countries<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. Moreover, other comorbidities and factors have been associated with more severe infection, such as diabetes, obesity, pre-existing end organ disease, hypertension, and male sex<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. It has been suggested that the cytokine storm is more easily triggered in patients with chronic inflammation, such as those with diabetes, obesity, and cardiac disease<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. The cause of high mortality in older BAME subjects reported in the UK and USA remains unclear, although role of comorbidities such as diabetes, hypertension, and obesity as well as social deprivation are implicated (<ext-link ext-link-type="uri" xlink:href="https://www.england.nhs.uk/coronavirus/workforce/addressing-impact-of-covid-19-on-bame-staff-in-the-nhs/">https://www.england.nhs.uk/coronavirus/workforce/addressing-impact-of-covid-19-on-bame-staff-in-the-nhs/</ext-link>).</p><p id="Par7">While the majority of infected people exhibit mild or moderate symptoms and do not require hospitalization, more severe patients need to be hospitalized and sometimes intubated due to severe respiratory distress<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Other serious consequences of COVID-19 include acute kidney injury, a coagulopathy similar to disseminated intravascular coagulation<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, thrombosis<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, and a newly recognized post-infection syndrome in children, known as multi-system inflammatory syndrome in children potentially associated with COVID-19<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. The sequelae of each of these syndromes can result in multi-organ failure<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par8">A significant number of those diagnosed with COVID-19 have reported a broad spectrum of neurological consequences<sup><xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref></sup>. Neurological symptoms include those associated with dysfunction of the central (fatigue, headache, confusion, stroke<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, dizziness, syncope<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, seizure, anorexia, and insomnia)<sup><xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref></sup>, peripheral (anosmia, ageusia, myoclonus<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>, neuropathic pain, and myalgias)<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>, combined central-peripheral (Guillain Barre syndrome<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>) and enteric nervous systems (diarrhea<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>). Some gastrointestinal manifestations, including diarrhea, may be related to the expression of the viral receptor ACE2 and a serine protease, transmembrane serine protease 2 (TMPRSS2), involved in S protein priming, in the small intestinal epithelia and colon<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.</p><p id="Par9">As many as 65% of COVID-19 affected individuals reported hyposmia and ageusia<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>, features that suggest the possibility of trans-synaptic spread via the olfactory, lingual, and glossopharyngeal nerves (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), secondary to a respiratory route of infection. Hyposmia is now officially recognized as a symptom of COVID-19 by the UK government and may be a sign in &#x0201c;asymptomatic&#x0201d; carriers who may not have upper respiratory tract symptoms.<fig id="Fig1"><label>Fig. 1</label><caption><title>Possible entry routes for SARS-CoV-2 into central nervous system and potential intracellular consequences.</title><p>There is evidence for SARS-CoV-2 invasion of vasculature in the brain, but little evidence for SARS-CoV-2 in brain parenchyma at this time: this issue will become clearer with results from ongoing autopsy studies. Whether or not the virus is present in neurons or astrocytes, there may be multiple consequences for brain cells, in part through intracellular responses to inflammation that could lead to protein misfolding, a feature of neurodegenerative disorders.</p></caption><graphic xlink:href="41531_2020_123_Fig1_HTML" id="d30e782"/></fig></p><p id="Par10">A recent review of 43 confirmed COVID-19 cases in a London, UK hospital suggested emergence of specific neurological presentations, including encephalopathies, inflammatory central nervous system syndromes, ischemic strokes, and peripheral neurological disorders, although parkinsonism and rates of hyposmia or ageusia were not reported<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>.</p><p id="Par11">We and others have previously flagged concerns regarding COVID-19 in people with Parkinson&#x02019;s disease (PD), especially for older and frail subjects with advanced PD who may be particularly vulnerable<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p></sec><sec id="Sec3"><title>Historical aspects of viruses and parkinsonism</title><p id="Par12">It is remarkable that a relationship between the presence of antibodies to coronaviruses that cause the common cold, coronavirus OC43 and 229E, in the cerebrospinal fluid (CSF) and Parkinson&#x02019;s disease was reported nearly twenty years prior to the current pandemic by Stanley Fahn and colleagues<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Prior coronaviruses have been occasionally reported to exhibit neurological manifestations and CSF invasion<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, including in children<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>.</p><p id="Par13">Medical history provides observations supporting links between viral infections and parkinsonism<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. The best known example is the post-encephalitic parkinsonism observed during the encephalitic lethargica outbreak that overlapped with the Spanish Flu (influenza A virus H1N1) pandemic in 1918<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. However, after 100 years, the cause of encephalitis lethargica still remains a mystery<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. While a causal role of influenza A H1N1 virus in the development of post-encephalitic parkinsonism is not confirmed<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>, an association between influenza A virus infection and development of transient parkinsonism is reported<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Notably, the avian flu resulted in parkinsonism in many survivors<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Other viral infections have been associated with the development of transient or, more rarely, permanent parkinsonism, including Epstein-Barr, Japanese encephalitis, Coxsackie, West Nile, Western equine encephalomyelitis, and human immunodeficiency virus, mostly due to induction of neuroinflammation and/or hypoxic brain injury with structural/functional damage within the basal ganglia<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup> (Table <xref rid="Tab1" ref-type="table">1</xref>). In addition, debated evidence suggests that previous infection with herpes simplex 1, Epstein-Barr, varicella zoster, hepatitis C, and influenza A virus can increase the risk of developing PD in the long-term<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Although the &#x0201c;viral hypothesis&#x0201c; was generally ignored after the discovery of genetic mutations involved in PD pathogenesis, the role of &#x0201c;environmental&#x0201d; factors acting as peripheral triggers of the neurodegenerative process in susceptible individuals has been increasingly acknowledged<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Mechanisms involved in the pathogenesis of viral-induced parkinsonism.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Mechanism</th><th>Type of neuronal damage</th></tr></thead><tbody><tr><td>Virus tropism for basal ganglia, replication and subsequent neuronal lysis</td><td>Direct</td></tr><tr><td>Microglia activation and release of pro-inflammatory factors and T cell response</td><td>Indirect</td></tr><tr><td>Hypercytokinemia and loss of vascular integrity</td><td>Indirect</td></tr><tr><td>Hypoxic brain injury</td><td>Indirect</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>SARS-CoV-2 receptors and cellular uptake</title><p id="Par14">There is a wide diversity of proteins, particularly glycoproteins, that act as cellular receptors for coronavirus spike proteins<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>.</p><p id="Par15">SARS-CoV-2 shares 70&#x02013;80% of its genome with SARS-CoV and a smaller but significant homology with MERS-CoV<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. This homology extends to the S protein<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> that is the point of attachment to plasma membrane proteins which act as viral receptors for cellular infection. The S protein is thought to require a priming step in which it is cleaved by a cellular protease, which for SARS-CoV and SARS-CoV-2 is reported to be the cellular serine protease, TMPRSS2<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>.</p><p id="Par16">The extensive research devoted to determining how the binding of the virus leads to cellular endocytosis of the virus, leading ultimately to RNA translation, transcription, and viral replication, will not be reviewed here.</p><p id="Par17">At this time it appears that the main protein responsible for cellular accumulation of SARS-CoV-2 is angiotensin-converting enzyme 2 (ACE2)<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup>, an enzyme that converts angiotensin II to angiotensin. ACE2 also acts as a receptor for several other coronavirus, including SARS-CoV<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>. The distribution of ACE2 throughout the body and brain is discussed below.</p><p id="Par18">Recent in-silico studies<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup> propose that, in addition to ACE2, a second mechanism may enable cellular endocytosis of SARS-CoV-2. Similar to MERS-CoV, and in contrast to SARS-CoV, SARS-CoV-2 appears to display high binding affinity to sialic acid residues, providing an additional candidate for binding. Sialic acid residues are found on plasma membrane proteins of many cell types, including neurons, and are very highly expressed in the upper respiratory tract.</p><p id="Par19">Additional observations that may test the predictions from in-silico reports implicating a role for sialic acid residues as SARS-CoV-2 receptors include (1) efficacy of the therapeutic use of lactoferrin<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, an antiviral agent that interacts with sialic acid residues; (2) an ongoing clinical trial of DAS181 (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04324489">https://clinicaltrials.gov/ct2/show/NCT04324489</ext-link>), a drug designed to block viral access by cleaving sialic acid; (3) that the shedding pattern of SARS-CoV-2 infection is different from that of SARS-CoV and more similar to that of &#x0201c;standard&#x0201d; influenza<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, where sialic acid receptors play a major role; (4) a bioinformatic study reports binding of S-protein to sialic acid glycans in a region close to that identified by the in silico studies<sup><xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup>. To our knowledge, while links between sialic acid and neurotropism for mouse hepatitis virus<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> and adenoviruses<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> have been suggested, there are no published investigations on this alternative pathway for SARS-CoV-2 interaction in the nervous system.</p><p id="Par20">There are additional strong candidates for receptors for the virus, including the lectin CD209L (also known as L-SIGN), which acts as a receptor for the SARS virus<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>. This should be analyzed both in the nervous system and additional tissues, as well as other suggested candidate coronavirus receptors, most of which are highly charged and glycosylated<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>.</p></sec><sec id="Sec5"><title>Potential neurotropism of COVID-19 virus</title><p id="Par21">At this time, we know very little about SARS-CoV-2 in the brain. Post-mortem studies on patients with SARS, however to have suggested the presence of viral particles in central nervous system (CNS) tissue<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR72">72</xref></sup>.</p><p id="Par22">A recent publication examining the localization of SARS-CoV-2 in 27 people who died from COVID-19 demonstrated that 36% had apparently low levels of SARS-CoV-2 RNA and proteins in the brain, although they did not report the cellular localization or regions examined, and the signals may not have been present within the brain parenchyma<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. A second study similarly reports detectable SARS-CoV-2 RNA in four of 12 brain samples, although again the signal may not have been from brain parenchymal cells<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>.</p><p id="Par23">While there is, at this time, little evidence that SARS-CoV-2 enters the brain parenchyma, there are multiple means by which the virus might be able to do so<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. Preclinical animal studies (reviewed by Natoli et al.<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>) report that after intranasal inoculation of SARS&#x02010;CoV in transgenic mice that overexpress human ACE2<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>, or MERS-CoV in mice overexpressing human dipeptidyl peptidase 4<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>, SARS&#x02010;CoV and MERS-CoV can invade the brain, possibly via transit through the olfactory nerves, to reach CNS nuclei, including thalamus and brainstem; we note, however, that these mice over-express the viral receptors, and these reports do not model normal infection routes.</p><p id="Par24">Trans-synaptic transfer has been documented in rat and pig for other types of coronavirus, including hemagglutinating encephalomyelitis virus (HEV)<sup><xref ref-type="bibr" rid="CR79">79</xref>&#x02013;<xref ref-type="bibr" rid="CR81">81</xref></sup> and avian infectious bronchitis virus (IBV, also known as avian coronavirus)<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>, in both in vitro and in vivo studies.</p><p id="Par25">Coronavirus might also reach the CNS via the hematogenous or lymphatic route, although this seems unlikely in early phases of the disease, as particles of SARS-CoV were not detected in non-neuronal cells in human post-mortem brain tissue<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR72">72</xref></sup>.</p><p id="Par26">One potential mechanism for SARS-CoV-2 RNA presence within the CNS is blood-brain barrier (BBB) breakdown due to the cytokine storm associated with peripheral viral infection. It is well established that pro-inflammatory cytokines associated with inflammation and/or SARS-CoV-2 viral infection, such as tumor necrosis factor (TNF) and interleukin 1 beta (IL-1beta), mediate BBB breakdown<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>. This breakdown could either be long-term, similar to the one observed in neurodegenerative diseases allowing for infiltration of immune cells and viral particles, or transient, resulting in encephalitis<sup><xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup>.</p><p id="Par27">We note that while there are at this time several millions of SARS-CoV-2 infected individuals, there are only a few reports suggesting possible encephalitis, and only two that show evidence of COVID-19 virus in the CSF as assessed by reverse transcription polymerase chain reaction (RT-PCR). This suggests that even with the presence of high viral load in the blood stream and severe inflammation, COVID-19 virus is unlikely to exhibit direct neurotropism, but rather appears to cause inflammatory-mediated brain responses<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>.</p></sec><sec id="Sec6"><title>Presence of SARS-CoV-2 receptors in the brain</title><p id="Par28">ACE2 was identified in 2000 as a novel carboxypeptidase that cleaves the vasoconstrictor angiotensin II to the vasodilator angiotensin (1&#x02013;7), in addition to cleaving several other peptides<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. ACE2 is a transmembrane protein, and can itself be cleaved near the transmembrane region and thereby be &#x0201c;shed&#x0201d; into a soluble form with anti-viral activity<sup><xref ref-type="bibr" rid="CR88">88</xref>,<xref ref-type="bibr" rid="CR89">89</xref></sup>, in part as the soluble form likely binds virus. Plasma membrane ACE2 is, confusingly, often referred to as the &#x0201c;ACE2 receptor&#x0201d;, but this is intended to convey that the protein, in addition to its normal function, can act as a receptor for virus&#x02014;and not that it is a receptor for ACE2.</p><p id="Par29">ACE2 is widely expressed in human tissue<sup><xref ref-type="bibr" rid="CR90">90</xref></sup> and appears to be increased by inflammatory signals including in macrophages<sup><xref ref-type="bibr" rid="CR91">91</xref></sup>. Evidence supporting ACE2 expression in human brain parenchyma, however, remains poor, in contrast to clear expression in the brain vessels<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>. There is an extensive literature indicating that ACE2 may serve as a protective stress-induced response pathway<sup><xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR95">95</xref></sup> and that its expression might be harnessed clinically for cardiac and neurological disorders, which will not be reviewed here.</p><p id="Par30">In particular, while ACE2 expression has been demonstrated in CNS neurons in some animal models<sup><xref ref-type="bibr" rid="CR96">96</xref>,<xref ref-type="bibr" rid="CR97">97</xref></sup>, the presence of ACE2 in human CNS neurons is not well established, nor are specific brain regions or neuronal, astrocyte, microglial, immune or vascular cell types well characterized.</p><p id="Par31">The ACE2 promoter harbors five hypoxia-responsive elements, and hypoxia may upregulate ACE2 via HIF1A-independent mechanisms<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>, but it has not yet been determined if hypoxia upregulates ACE2 in brain cells.</p><p id="Par32">It is very important to compare the presence of brain ACE2, and perhaps of CD209L and molecules with sialic acid residues, in both control individuals and those with high inflammation. The expression of some of these &#x0201c;receptors&#x0201d;, including ACE2, can be enhanced by cytokines, such as interferon<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>, or other inflammatory responses<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>, and may be regulated by excitotoxicity<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>.</p><p id="Par33">The Human Protein Atlas reports that ACE2 is not detected in normal human brain, but indicates low amounts in mouse brain (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/ENSG00000130234-ACE2/tissue">https://www.proteinatlas.org/ENSG00000130234-ACE2/tissue</ext-link>). As mentioned, an immunocytochemistry study of human brain tissue indicated that ACE2 is present in non-neuronal cells of vasculature in human brain tissue<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>, although that study did not define the precise cell types that express the receptor. A preprint of a single cell transcriptomic analysis suggests differential levels of ACE2 mRNA in different mouse brain regions<sup><xref ref-type="bibr" rid="CR101">101</xref></sup>. Another preprint features a meta-analysis of single-cell and single-nucleus RNA sequencing datasets indicating co-expression of ACE2 and TMPRSS2 in oligodendrocytes<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>. However, additional studies are required to validate and localize protein co-expression in the CNS.</p><p id="Par34">Because SARS-CoV-2 proteins can interact with host proteins involved in pathways that are altered during aging, including potential mitochondrial dysfunction, loss of proteostasis, autophagy dysfunction, inflammation, and endoplasmic reticulum stress, it is possible that SARS-CoV-2 infection may prompt protein misfolding and aggregation (Fig. <xref rid="Fig1" ref-type="fig">1</xref>)<sup><xref ref-type="bibr" rid="CR103">103</xref>&#x02013;<xref ref-type="bibr" rid="CR105">105</xref></sup>. Of particular relevance for PD, recent studies have suggested that the aggregation-prone protein, alpha-synuclein, plays a role in the innate immune response to viral infections<sup><xref ref-type="bibr" rid="CR106">106</xref>,<xref ref-type="bibr" rid="CR107">107</xref></sup>.</p><p id="Par35">It will be important to follow up and clinically monitor patients infected by COVID-19 virus, particularly those who developed specific neurological disturbances, such as sustained hyposmia<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>, syncope, and persistent confusion, given the relevance of these conditions to PD and PD dementia. Hyposmia is a well-recognized prodromal feature of PD<sup><xref ref-type="bibr" rid="CR109">109</xref></sup> as well as Alzheimer&#x02019;s disease<sup><xref ref-type="bibr" rid="CR110">110</xref></sup> and may be due in part to dysfunction of inhibitory dopaminergic neurons in the olfactory bulb<sup><xref ref-type="bibr" rid="CR111">111</xref></sup>. Although we do not yet know the precise mechanisms underlying hyposmia in COVID-19, it may be that patients who develop hyposmia become more susceptible to a neurodegenerative process or, alternatively, hyposmia may be a sign of peripheral inflammatory involvement of the olfactory mucosa. It is, therefore, reasonable to suggest specifically following up those COVID-19-linked cases where recovery is associated with sustained hyposmia after the acute illness of COVID-19 has subsided.</p></sec><sec id="Sec7"><title>COVID-19 and the possibility of a post-viral parkinsonism: clinical and molecular rationales</title><p id="Par36">Some literature has already highlighted potential links between COVID-19 virus and neurodegenerative conditions, including suggestions regarding PD<sup><xref ref-type="bibr" rid="CR104">104</xref>,<xref ref-type="bibr" rid="CR112">112</xref></sup>. These are based on multiple observations:<list list-type="order"><list-item><p id="Par37">The ability of coronaviruses to enter the CNS through the nasal cavity with subsequent neuronal death<sup><xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR78">78</xref></sup>, as shown in animal studies.</p></list-item><list-item><p id="Par38">Hyposmia is well documented in COVID-19 patients without nasal obstruction and rhinorrhea<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR113">113</xref>,<xref ref-type="bibr" rid="CR114">114</xref></sup> and is also a common prodromal feature of PD<sup><xref ref-type="bibr" rid="CR115">115</xref></sup>.</p></list-item><list-item><p id="Par39">Basal ganglia lesions may occur in the context of a thromboembolic encephalopathy in COVID-19<sup><xref ref-type="bibr" rid="CR116">116</xref></sup>.</p></list-item><list-item><p id="Par40">The presence of higher levels of antibodies against other coronaviruses that cause the common cold in the CSF of PD patients compared to healthy controls suggests a possible involvement of viral infection in the pathogenesis of PD<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>.</p></list-item><list-item><p id="Par41">There are reports that ACE2 may be expressed in various regions of the nervous system<sup><xref ref-type="bibr" rid="CR93">93</xref>,<xref ref-type="bibr" rid="CR117">117</xref></sup>, although as detailed above, further neuropathological investigation is required. Given the interferon activation of this protein, it will be important to examine subjects with CNS inflammation or encephalitis.</p></list-item><list-item><p id="Par42">The recent reports of syncope with no abnormal rhythms on cardiac device interrogation hint at a potential role for neurally-mediated syncope<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> vs. orthostasis, suggesting the importance of these investigations for PD patients who often suffer from dysautonomia<sup><xref ref-type="bibr" rid="CR118">118</xref></sup>.</p></list-item><list-item><p id="Par43">A single case report of a patient who developed myoclonus and an acute but spontaneously reversible hypokinetic rigid syndrome, with DaTscan showing reduction of dopamine transporter uptake in the putamen as well as hyposmia<sup><xref ref-type="bibr" rid="CR119">119</xref></sup>.</p></list-item><list-item><p id="Par44">The angiotensin system, which is implicated in COVID-19 pathogenesis, may be important in neuroinflammatory and neurodegenerative mechanisms observed in PD<sup><xref ref-type="bibr" rid="CR120">120</xref>,<xref ref-type="bibr" rid="CR121">121</xref></sup>.</p></list-item><list-item><p id="Par45">SARS-CoV-2 proteins can interact with human proteins involved in biological mechanisms that drive dysfunction of protein homeostasis that may lead to protein misfolding and aggregation (Fig. <xref rid="Fig1" ref-type="fig">1</xref>)<sup><xref ref-type="bibr" rid="CR103">103</xref>,<xref ref-type="bibr" rid="CR104">104</xref></sup>.</p></list-item><list-item><p id="Par46">The release of cytokines may activate resident immune cells in the CNS and/or lead to their infiltration from the periphery that result in brain cell damage. Such cells may include activated T cells and microglia that may kill neurons<sup><xref ref-type="bibr" rid="CR122">122</xref>&#x02013;<xref ref-type="bibr" rid="CR124">124</xref></sup>, astrocytes, and vascular cell types. This may occur through the selection of cells that specifically recognize presented antigens from the infection or previous infections, or via a general activation of cytotoxic cells that recognize other antigens, including autoantigens, such as those derived from alpha-synuclein which are implicated in PD, Lewy Body dementias, multiple system atrophy, and multiple sclerosis<sup><xref ref-type="bibr" rid="CR125">125</xref>,<xref ref-type="bibr" rid="CR126">126</xref></sup>. High levels of pro-inflammatory cytokines, such as TNF and IL-1beta, are associated with increased risk of PD, while use of non-steroidal anti-inflammatory drugs (NSAIDs) and anti-TNF biologics reduce the risk<sup><xref ref-type="bibr" rid="CR127">127</xref></sup>. Anti-TNF biologics are currently under investigation for COVID-19.</p></list-item></list></p><p id="Par47">Beyond the significant observational literature discussed above that suggests a relationship between viral infection and PD<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, a number of preclinical studies have directly addressed this issue. Jang et al. examined the potential for a neurotropic Type A influenza virus (A/Vietnam, 1203/04, H5N1, a.k.a. bird flu) to induce parkinsonian pathology in mice. They found that this strain of influenza virus directly infected neurons, with particular affinity for circuits involved in PD. Subsequent to recovery from this infection, the mice exhibited ataxia, tremor, and bradykinesia<sup><xref ref-type="bibr" rid="CR128">128</xref></sup> as well as a transient but significant loss of dopaminergic neuron phenotype, an early neuroinflammatory program, long-lasting microgliosis and an increase in alpha-synuclein expression<sup><xref ref-type="bibr" rid="CR129">129</xref></sup>.</p><p id="Par48">Another neurotropic virus, the mosquito-borne alphavirus, Western equine encephalitic virus (WEEV) also induces post-encephalitic parkinsonism. Like the influenza virus, WEEV induced activation of microglia and astrocytes, selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and behavioral abnormalities consistent with PD in mouse models<sup><xref ref-type="bibr" rid="CR130">130</xref></sup>. Importantly, the common denominator of these viruses is that they enter the CNS and directly infect cells.</p><p id="Par49">As we do not yet know if the SARS-CoV-2 virus directly infects CNS neurons, it is important to determine if non-neurotropic viruses also have the potential to contribute to development of PD. The idea that a peripheral cytokine storm from non-neurotropic viruses can induce encephalitis has been suggested for many other viral infections, including the 1918 Spanish influenza (Type A H1N1)<sup><xref ref-type="bibr" rid="CR131">131</xref>,<xref ref-type="bibr" rid="CR132">132</xref></sup> as well as respiratory syncytial virus<sup><xref ref-type="bibr" rid="CR133">133</xref></sup>.</p><p id="Par50">Notably, the pandemic 2009 H1N1 (CA/09) influenza virus does not infect neurons in the central, peripheral or enteric nervous systems, but can nevertheless induce a significant inflammatory response in the CNS, including within the SNpc. Evidence that an indirect neuroinflammatory mechanism of this sort might increase the risk of parkinsonism is that mice infected with the 2009 H1N1 virus, after complete resolution of peripheral infection, displayed a higher level of SNpc DA neuron death after injection with the parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Administration of an influenza vaccine or the neuraminidase inhibitor oseltamivir (Tamiflu) protected against the synergistic response to the neurotoxin<sup><xref ref-type="bibr" rid="CR134">134</xref></sup>. In these preclinical studies, microgliosis and increase in inflammatory cytokines and chemokines in the brain were not due to invasion of CD4+/CD8+ T-cells from the periphery, suggesting that inflammatory cytokines released during peripheral infection passed through the blood-brain barrier<sup><xref ref-type="bibr" rid="CR135">135</xref></sup> and indirectly activated microglia, leading to a parkinsonian cascade.</p><p id="Par51">Interestingly, influenza vaccination in humans enhanced levels of the anti-inflammatory cytokine interleukin 10 (IL-10)<sup><xref ref-type="bibr" rid="CR136">136</xref></sup>, while prophylactic treatment with oseltamivir (Tamiflu) decreased disease severity of influenza in both human and mouse models, and did not appear to interfere with appropriate T cell responses to new influenza infection<sup><xref ref-type="bibr" rid="CR137">137</xref></sup>. It may be that vaccination is protective for nervous system inflammatory responses even from viruses that do not infect neurons and astrocytes.</p></sec><sec id="Sec8"><title>The need for detailed autopsy studies</title><p id="Par52">As deaths from SARS-CoV-2 infection continue, autopsy studies will play a key role in defining CNS pathology, including in patients with PD. However, due to increased precautions taken at the time of autopsy, relatively few brain autopsies are being performed. The U.S. Centers for Disease Control has issued guidance on autopsies for confirmed SARS-CoV-2 decedents and advises against performing procedures that generate aerosols, such as those used to remove the brain (<ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html#biosafety">https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html#biosafety</ext-link>). Most studies thus far lack neuropathologic characterization altogether<sup><xref ref-type="bibr" rid="CR138">138</xref>&#x02013;<xref ref-type="bibr" rid="CR142">142</xref></sup>, and an autopsy case series did not provide detailed neuropathologic descriptions<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. Moreover, deaths occurring in nursing home and long-term care facilities, where a large subset of patients suffering from dementia reside, are less likely to result in autopsies. We thus expect a delay in understanding whether and how SARS-CoV-2 infection specifically alters neuropathology, including in PD.</p><p id="Par53">Of the available studies with some neuropathologic data, one case series of ten autopsies documented no signs of encephalitis or CNS vasculitis, although the extent of neuroanatomic sampling was not provided<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. A second study of COVID-19 autopsy findings included four brains that exhibited no encephalitis or neuronal necrosis, but mild hypoxemic changes in three of the four brains examined<sup><xref ref-type="bibr" rid="CR143">143</xref></sup>. Although these studies have not identified specific neuropathologic alterations, the extent of involvement of the CNS in SARS-CoV-2 infection cannot be inferred from only 14 brains.</p><p id="Par54">To establish how SARS-CoV-2 infection affects the CNS, the field will require detailed neuropathologic studies with thorough sampling of specific brain regions. At the Columbia University Medical Center, a current approach involves sampling of multiple neuroanatomic regions, including the cerebral cortex, watershed areas, white matter, olfactory system, hippocampus, amygdala, thalamus, hypothalamus, corpus striatum, pallidum, cerebellum, midbrain, pons, medulla oblongata, and cervical cord. We recommend that special attention be directed at documenting the presence and neuroanatomic distribution of hypoxia-related as well as inflammation-related pathologies, including leptomeningitis, encephalitis, and vasculitis.</p></sec><sec id="Sec9"><title>The clinical perspective</title><p id="Par55">Clinical implications of SARS-CoV-2 infection on PD are largely speculative apart from two case series and case reports<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. A community-based case control study in Italy of 12 PD COVID-19 cases suggested substantial worsening of motor and non-motor symptoms during mild to moderate COVID-19 illness, independent of age and disease duration<sup><xref ref-type="bibr" rid="CR144">144</xref></sup>, in line with an original case report series by Antonini et al. In another survey across the Lombardy region of Italy, 105 probable COVID-19 cases were identified and the authors concluded that the risk, morbidity, and mortality in patients with mild-to moderate PD with COVID-19 did not differ from the general population<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>. Several viewpoints and editorials have been published on the topic in addition to extensive coverage in social media and journal viewpoint papers<sup><xref ref-type="bibr" rid="CR146">146</xref>&#x02013;<xref ref-type="bibr" rid="CR151">151</xref></sup>.</p><p id="Par56">Currently there is no robust evidence that having PD imparts an increased risk for susceptibility to COVID-19 or that COVID-19 confers a greater risk of PD, although, as noted above, there are reported cases of worsening of PD symptoms in infected patients, particularly in older frail patients on advanced therapies and one case report of development of an acute hypokinetic syndrome with hyposmia post COVID-19.</p><p id="Par57">Broadly, the clinical impact of COVID-19 on PD could occur through multiple avenues:<list list-type="order"><list-item><p id="Par58">Development of COVID-19-related symptoms, particularly high fever, severe respiratory distress, coagulopathy-related syndrome, fatigue, myalgias, and related impaired stress mechanisms.</p></list-item><list-item><p id="Par59">Worsening of pre-existing dyspnea due to respiratory distress; dyspnea may exist in up to 39% of PD patients<sup><xref ref-type="bibr" rid="CR152">152</xref></sup>.</p></list-item><list-item><p id="Par60">In acutely ill patients admitted to hospital, confusion and delirium could occur (reported in over 25% of COVID-19 hospitalized subjects out of a survey of 3500 patients)<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>.</p></list-item><list-item><p id="Par61">Worsening of specific symptoms, including motor symptoms as well as non-motor issues, such as pain, anxiety, sleep disturbances and fatigue, especially with reduced access to physical therapy and counseling<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR144">144</xref></sup>.</p></list-item><list-item><p id="Par62">Social isolation and aggravation of underlying cognitive and behavioral symptoms, specifically anxiety<sup><xref ref-type="bibr" rid="CR153">153</xref></sup>.</p></list-item><list-item><p id="Par63">Possibility of post-traumatic stress disorder (PTSD) as observed in previous SARS and MERS pandemics<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>.</p></list-item><list-item><p id="Par64">Increased levodopa requirement during acute admissions and need for non-oral dopaminergic therapies in some subjects with severe COVID-19 related symptoms<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>.</p></list-item><list-item><p id="Par65">Potential for drug interaction of over the counter cough remedies with anti-parkinsonian drugs such as monoamine oxidase inhibitors.</p></list-item><list-item><p id="Par66">Complexity in therapeutic management related to limitations of in-person consultations and admissions to hospital<sup><xref ref-type="bibr" rid="CR147">147</xref></sup>.</p></list-item></list></p><p id="Par67">The impact of severe infection (by default, implying a high viral load or a pro-inflammatory state) may lead to hospitalization and the need for supported breathing or mechanical ventilation, particularly in older PD patients with multimorbidity and a high frailty index<sup><xref ref-type="bibr" rid="CR154">154</xref></sup>. The issue is further compounded because such patients may be on non-oral therapies (subcutaneous apomorphine, intrajejunal levodopa infusion, and deep brain stimulation (DBS)) for advanced PD<sup><xref ref-type="bibr" rid="CR151">151</xref></sup>. Limited observations from admission of such cases around the world (personal communication) and the published case series suggest that such patients are particularly vulnerable, with high mortality rates and may have an increased levodopa requirement during the acute illness<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. Pre-existing dyspnea of PD<sup><xref ref-type="bibr" rid="CR152">152</xref>,<xref ref-type="bibr" rid="CR155">155</xref></sup>, respiratory muscle bradykinesia<sup><xref ref-type="bibr" rid="CR155">155</xref></sup> in addition to a possible direct SARS-CoV-2-related brainstem-generated suppression of cough reflex and perhaps of autoregulation of blood flow may play additional negative roles<sup><xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR78">78</xref>,<xref ref-type="bibr" rid="CR156">156</xref>,<xref ref-type="bibr" rid="CR157">157</xref></sup>.</p><p id="Par68">Fatigue has been commonly reported after many viral infections, most notably with Epstein-Barr virus<sup><xref ref-type="bibr" rid="CR158">158</xref></sup>, and is evident in many non-PD cases with COVID-19<sup><xref ref-type="bibr" rid="CR159">159</xref></sup>. Fatigue was also common in the series of PD cases reported<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> and is an important contributor of quality of life<sup><xref ref-type="bibr" rid="CR160">160</xref></sup>. Myalgia is also common after viral illnesses including COVID-19<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR161">161</xref></sup>, and in some cases of COVID-19 with PD, myalgia can be severe and involve muscles of the back. If these observations are confirmed in larger cohorts of PD patients with COVID-19, specific anti-fatigue/myalgia measures may need to be implemented<sup><xref ref-type="bibr" rid="CR160">160</xref></sup>. Consideration for the use of amantadine-like drugs may be particularly relevant given their putative antiviral effects<sup><xref ref-type="bibr" rid="CR162">162</xref>,<xref ref-type="bibr" rid="CR163">163</xref></sup>; however specific clinical trials are lacking.</p><p id="Par69">Social isolation and its impact on PD are a concern and has been called a &#x0201c;hidden sorrow&#x0201d; of the pandemic<sup><xref ref-type="bibr" rid="CR164">164</xref></sup>. Social isolation may cause heightened anxiety, aggravation of pre-existing depression, the negative effects of stress on PD<sup><xref ref-type="bibr" rid="CR165">165</xref></sup>, as well as lack of exercise. In the previous SARS and MERS epidemics, one in three hospitalized cases went on to develop a PTSD with 15% developing depression and anxiety at 1 year, and fatigue in more than 15%<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Anxiety in PD during COVID-19-related lockdown and consequent stress is widely reported during telephone consultations in many countries, and specific strategies for home care using telemedicine or remote counselling may need to be implemented.</p><p id="Par70">An overall consensus-led guideline for management of PD with varying grades of COVID-19 needs to be developed and circulated for implementation. A suggested template is provided in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. These observations can be applied to the elderly as well as subjects with other neurodegenerative disorders, such as Alzheimer&#x02019;s disease or amyotrophic lateral sclerosis.<fig id="Fig2"><label>Fig. 2</label><caption><title>Flowchart identifying potential management issues in Parkinson&#x02019;s disease patients.</title><p><bold>a</bold> Parkinson&#x02019;s disease patients exposed to self-isolation or <bold>b</bold>, <bold>c</bold> infection with Coronavirus disease 2019 virus.</p></caption><graphic xlink:href="41531_2020_123_Fig2_HTML" id="d30e1685"/></fig></p></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusions</title><p id="Par71">There has been a large number of papers on COVID-19 and PD speculating on etiology, risks and consequences, in addition to two documented case series of PD with COVID-19. We attempt to prove a critical approach to these observations from currently available clinical and molecular insights.<list list-type="bullet"><list-item><p id="Par72">The COVID-19 pandemic has led to an unprecedented crisis for older people globally. There is a broad range of COVID-19 symptoms, perhaps related to pre-existing conditions and in part to different modes of viral entry and the presence of T cells that are reactive to prior coronavirus infections. The neurological manifestations may be related to inflammation involving capillaries and the blood-brain barrier, hypoxemia, and thrombosis acting as triggers for seizures or leading to ischemic or hemorrhagic strokes.</p></list-item><list-item><p id="Par73">Neuropathology studies have not yet clearly answered the central issue of whether the virus enters central nervous system neurons, astrocytes or microglia.</p></list-item><list-item><p id="Par74">In brain vasculature, the cell types that express virus have not yet been identified.</p></list-item><list-item><p id="Par75">There is no clear evidence in human neurons or astrocytes for expression of the protein ACE2, which is thought to act as the major viral receptor that enables viral entry. Such expression may, however, be activated by inflammation, and thus comparison of healthy and infected brains will be important.</p></list-item><list-item><p id="Par76">There is a variety of alternative viral receptors for coronavirus, including sialic acid residues, that are insufficiently characterized and may provide entry into neurons and astrocytes.</p></list-item><list-item><p id="Par77">In contrast to the 1918 influenza pandemic and avian flu, reports of encephalopathy in COVID-19 have been slow to emerge, and there are so far no documented reports of an induction of parkinsonism apart from a single report. While a role for the virus in causing or exacerbating Parkinson&#x02019;s disease appears unlikely at this time, the aggravation of specific motor and non-motor symptoms is reported.</p></list-item><list-item><p id="Par78">As the prevalence of PD rises sharply in the older age group, particularly in those over the age of 80 years, a personalized approach in the management of PD patients affected by COVID-19 based on clinical and basic science evidence is required. In addition, it will be important to monitor subjects after recovery, particularly for those with persisting hyposmia.</p></list-item></list></p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank David Standaert and Ted Dawson for commentary and suggestions. We thank Ori Lieberman for the proofreading of the manuscript. Figure 1 was created with BioRender.com. The authors acknowledge the National Institute for Health Research (NIHR) London South Clinical Research Network and the NIHR Biomedical Research Centre. This article represents independent collaborative research part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King&#x02019;s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>K.R.C. and A.A. conceived of the idea. K.R.C., D.S., A.A., and V.L. wrote the first draft of the paper and revised subsequent drafts. A.N., R.J.S., J.E.G., O.A., L.Z., A.S., L.B., O.M., E.M., A.S.H., Y.X., and S.F. contributed to conception, critical review, and revision of paper; all authors approved the final draft for submission.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data sharing not applicable to this article as no data sets were generated or analyzed during the current study.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par79">D.S. and K.R.C. are Editors in Chief for <italic>npj Parkinson&#x02019;s</italic>
<italic>Disease</italic>. E.M. is Associate Editor for <italic>npj Parkinson&#x02019;s</italic>
<italic>Disease</italic>. A.A has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, AbbVie, Zambon, Bial, Ever Pharma, Neuroderm, Theravance Biopharma, Biogen, outside the submitted work; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - PD_Pal Grant 825785, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation, outside the submitted work. He serves as consultant for Boehringer&#x02013;Ingelheim for legal cases on pathological gambling, outside the submitted work. V.L., A.N., R.J.S., J.E.G., O.A., L.Z., A.S., L.B., O.M., A.S.H., Y.X., and S.F. declare that there are no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>ZW</given-names></name><etal/></person-group><article-title>Zoonotic origins of human coronaviruses</article-title><source>Int. J. Biol. Sci.</source><year>2020</year><volume>16</volume><fpage>1686</fpage><lpage>1697</lpage><?supplied-pmid 32226286?><pub-id pub-id-type="pmid">32226286</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Pascua</surname><given-names>PN</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name></person-group><article-title>Avian influenza a viruses: evolution and zoonotic infection</article-title><source>Semin. Respir. Crit. Care. Med.</source><year>2016</year><volume>37</volume><fpage>501</fpage><lpage>511</lpage><?supplied-pmid 27486732?><pub-id pub-id-type="pmid">27486732</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Morens, D. M., Taubenberger, J. K. &#x00026; Fauci, A. S. H7N9 avian influenza A virus and the perpetual challenge of potential human pandemicity. <italic>mBio</italic><bold>4</bold>. 10.1055/s-0036-1584953 (2013).</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Mostafa, A., Abdelwhab, E. M., Mettenleiter, T. C. &#x00026; Pleschka, S. Zoonotic potential of influenza A Viruses: a comprehensive overview. <italic>Viruses.</italic>10.3390/v10090497 (2018).</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reperant</surname><given-names>LA</given-names></name><name><surname>Kuiken</surname><given-names>T</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name><name><surname>Webby</surname><given-names>RJ</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name></person-group><article-title>Influenza viruses: from birds to humans. Emergence of influenza A viruses</article-title><source>Hum. Vaccin. Immunother.</source><year>2012</year><volume>8</volume><fpage>7</fpage><lpage>16</lpage><?supplied-pmid 22251997?><pub-id pub-id-type="pmid">22251997</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>RG</given-names></name></person-group><article-title>Influenza virus: transmission between species and relevance to emergence of the next human pandemic</article-title><source>Arch. Virol. Suppl.</source><year>1997</year><volume>13</volume><fpage>105</fpage><lpage>113</lpage><?supplied-pmid 9413531?><pub-id pub-id-type="pmid">9413531</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>AM</given-names></name><name><surname>Noymer</surname><given-names>A</given-names></name></person-group><article-title>Influenza mortality in the United States, 2009 pandemic: burden, timing and age distribution</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e64198</fpage><?supplied-pmid 23717567?><pub-id pub-id-type="pmid">23717567</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salamatbakhsh</surname><given-names>M</given-names></name><name><surname>Mobaraki</surname><given-names>K</given-names></name><name><surname>Sadeghimohammadi</surname><given-names>S</given-names></name><name><surname>Ahmadzadeh</surname><given-names>J</given-names></name></person-group><article-title>The global burden of premature mortality due to the Middle East respiratory syndrome (MERS) using standard expected years of life lost, 2012 to 2019</article-title><source>BMC Public Health</source><year>2019</year><volume>19</volume><fpage>1523</fpage><?supplied-pmid 31727042?><pub-id pub-id-type="pmid">31727042</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name></person-group><article-title>SARS-CoV-2: an emerging coronavirus that causes a global threat</article-title><source>Int. J. Biol. Sci.</source><year>2020</year><volume>16</volume><fpage>1678</fpage><lpage>1685</lpage><?supplied-pmid 32226285?><pub-id pub-id-type="pmid">32226285</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astuti</surname><given-names>I</given-names></name><name><surname>Ysrafil</surname></name></person-group><article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response</article-title><source>Diabetes Metab. Syndr.</source><year>2020</year><volume>14</volume><fpage>407</fpage><lpage>412</lpage><?supplied-pmid 32335367?><pub-id pub-id-type="pmid">32335367</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>507</fpage><lpage>513</lpage><?supplied-pmid 32007143?><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. <italic>Cell.</italic>10.1016/j.cell.2020.05.015 (2020).</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>COVID-19: gastrointestinal manifestations and potential fecal-oral transmission</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><fpage>1518</fpage><lpage>1519</lpage><?supplied-pmid 32142785?><pub-id pub-id-type="pmid">32142785</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahid</surname><given-names>Z</given-names></name><etal/></person-group><article-title>COVID-19 and older adults: what we know</article-title><source>J. Am. Geriatr. Soc.</source><year>2020</year><volume>68</volume><fpage>926</fpage><lpage>929</lpage><?supplied-pmid 32255507?><pub-id pub-id-type="pmid">32255507</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehndiratta</surname><given-names>MM</given-names></name><name><surname>Mehndiratta</surname><given-names>P</given-names></name><name><surname>Pande</surname><given-names>R</given-names></name></person-group><article-title>Poliomyelitis: historical facts, epidemiology, and current challenges in eradication</article-title><source>Neurohospitalist</source><year>2014</year><volume>4</volume><fpage>223</fpage><lpage>229</lpage><?supplied-pmid 25360208?><pub-id pub-id-type="pmid">25360208</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Dowd</surname><given-names>A</given-names></name></person-group><article-title>Covid-19: deaths in care home deaths in England and Wales rise sharply</article-title><source>BMJ (Clin. Res. ed.)</source><year>2020</year><volume>369</volume><fpage>m1727</fpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbatecola</surname><given-names>AM</given-names></name><name><surname>Antonelli-Incalzi</surname><given-names>R</given-names></name></person-group><article-title>Editorial: COVID-19 spiraling of frailty in older Italian patients</article-title><source>J. Nutr. Health Aging</source><year>2020</year><volume>24</volume><fpage>453</fpage><lpage>455</lpage><?supplied-pmid 32346677?><pub-id pub-id-type="pmid">32346677</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis</article-title><source>Aging (Albany NY)</source><year>2020</year><volume>12</volume><fpage>6049</fpage><lpage>6057</lpage><pub-id pub-id-type="pmid">32267833</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019&#x02014;COVID-NET, 14 States, March 1&#x02013;30, 2020</article-title><source>MMWR Morb. Moral. Wkly Rep.</source><year>2020</year><volume>69</volume><fpage>458</fpage><lpage>464</lpage></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Miossec, P. Understanding the cytokine storm during COVID-19: contribution of preexisting chronic inflammation. <italic>Eur. J. Rheumatol.</italic>10.5152/eurjrheum.2020.2062 (2020).</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goh</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from COVID-19 infection</article-title><source>Ann. Acad. Med. Singap.</source><year>2020</year><volume>49</volume><fpage>108</fpage><lpage>118</lpage><?supplied-pmid 32200400?><pub-id pub-id-type="pmid">32200400</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Harenberg, J. &#x00026; Favaloro, E. COVID-19: progression of disease and intravascular coagulation - present status and future perspectives. <italic>Clin. Chem. Lab</italic>. <italic>Med.</italic>10.1515/cclm-2020-0502 (2020).</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Levi, M., Thachil, J., Iba, T. &#x00026; Levy, J. H. Coagulation abnormalities and thrombosis in patients with COVID-19. <italic>Lancet Haematol.</italic>10.1016/s2352-3026(20)30145-9 (2020).</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Chiotos, K. et al. Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series. <italic>J. Pediatric Infect. Dis. Soc.</italic>10.1093/jpids/piaa069 (2020).</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Jose, R. J. &#x00026; Manuel, A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. <italic>Lancet Respir. Med.</italic>10.1016/s2213-2600(20)30216-2 (2020).</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Mao, L. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. <italic>JAMA Neurol.</italic>10.1001/jamaneurol.2020.1127 (2020).</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Esposito, G. et al. Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion? <italic>Brain. Behav. Immun.</italic>10.1016/j.bbi.2020.04.060 (2020).</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Li, Y. C., Bai, W. Z. &#x00026; Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. <italic>J. Med. Virol.</italic>10.1002/jmv.25728 (2020).</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriguchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>A first case of meningitis/encephalitis associated with SARS-Coronavirus-2</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>94</volume><fpage>55</fpage><lpage>58</lpage><?supplied-pmid 32251791?><pub-id pub-id-type="pmid">32251791</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">De Felice, F. G., Tovar-Moll, F., Moll, J., Munoz, D. P. &#x00026; Ferreira, S. T. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous system. <italic>Trends Neurosci.</italic>10.1016/j.tins.2020.04.004 (2020).</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Paniz-Mondolfi, A. et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). <italic>J. Med. Virol</italic>. 10.1002/jmv.25915 (2020).</mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Poyiadji, N. et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI Features. <italic>Radiology</italic>. 10.1148/radiol.2020201187 (2020).</mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Beyrouti, R. et al. Characteristics of ischaemic stroke associated with COVID-19. <italic>J. Neurol. Neurosurg. Psychiatry</italic>10.1136/jnnp-2020-323586 (2020).</mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Ebrille, E. et al. Syncope as the presenting symptom of COVID-19 infection. <italic>HeartRhythm Case Rep.</italic>10.1016/j.hrcr.2020.04.015 (2020).</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Lechien, J. R. et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. <italic>J. Intern. Med.</italic>10.1111/joim.13089 (2020).</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotfis</surname><given-names>K</given-names></name><etal/></person-group><article-title>COVID-19: ICU delirium management during SARS-CoV-2 pandemic</article-title><source>Crit. Care</source><year>2020</year><volume>24</volume><fpage>176</fpage><?supplied-pmid 32345343?><pub-id pub-id-type="pmid">32345343</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Zanin, L. et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. <italic>Acta Neurochir. (Wien).</italic>10.1007/s00701-020-04374-x (2020).</mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Rogers, J. P. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. <italic>Lancet Psychiatry</italic>. 10.1016/S2215-0366(20)30203-0 (2020).</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">R&#x000e1;bano-Su&#x000e1;rez, P. et al. Generalized myoclonus in COVID-19. <italic>Neurology.</italic>10.1212/wnl.0000000000009829 (2020).</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1061</fpage><lpage>1069</lpage></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Toscano, G. et al. Guillain-Barr&#x000e9; syndrome associated with SARS-CoV-2. <italic>N. Engl. J. Med.</italic>10.1056/NEJMc2009191 (2020).</mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amico</surname><given-names>F</given-names></name><name><surname>Baumgart</surname><given-names>DC</given-names></name><name><surname>Danese</surname><given-names>S</given-names></name><name><surname>Peyrin-Biroulet</surname><given-names>L</given-names></name></person-group><article-title>Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2020</year><volume>18</volume><fpage>1663</fpage><lpage>1672</lpage><?supplied-pmid 32278065?><pub-id pub-id-type="pmid">32278065</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Menni, C. et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. <italic>Nat. Med.</italic>10.1038/s41591-020-0916-2 (2020).</mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Paterson, R. W. et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. <italic>Brain.</italic>10.1093/brain/awaa240 (2020).</mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Antonini, A., Leta, V., Teo, J. &#x00026; Chaudhuri, K. R. Outcome of Parkinson&#x02019;s disease patients affected by COVID-19. <italic>Mov. Disord.</italic>10.1002/mds.28104 (2020).</mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Hainque, E., G., D. Rapid worsening in Parkinson&#x02019;s disease may hide COVID-19 infection. <italic>Parkinsonism Relat. Disord.</italic>10.1016/j.parkreldis.2020.05.008 (2020).</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazzini</surname><given-names>E</given-names></name><name><surname>Fleming</surname><given-names>J</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name></person-group><article-title>Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson&#x02019;s disease</article-title><source>Mov. Disord.</source><year>1992</year><volume>7</volume><fpage>153</fpage><lpage>158</lpage><?supplied-pmid 1316552?><pub-id pub-id-type="pmid">1316552</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)</article-title><source>Infection</source><year>2015</year><volume>43</volume><fpage>495</fpage><lpage>501</lpage><?supplied-pmid 25600929?><pub-id pub-id-type="pmid">25600929</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>EA</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>ME</given-names></name><name><surname>Duffner</surname><given-names>PK</given-names></name><name><surname>Faden</surname><given-names>H</given-names></name></person-group><article-title>Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis</article-title><source>Pediatrics</source><year>2004</year><volume>113</volume><fpage>e73</fpage><lpage>e76</lpage><?supplied-pmid 14702500?><pub-id pub-id-type="pmid">14702500</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>A</given-names></name><name><surname>Edner</surname><given-names>N</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Ternhag</surname><given-names>A</given-names></name></person-group><article-title>Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child</article-title><source>Infect. Dis. (Lond.)</source><year>2020</year><volume>52</volume><fpage>419</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">32067542</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Boltz</surname><given-names>DA</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name><name><surname>Smeyne</surname><given-names>RJ</given-names></name></person-group><article-title>Viral parkinsonism</article-title><source>Biochim. Biophys. Acta</source><year>2009</year><volume>1792</volume><fpage>714</fpage><lpage>721</lpage><?supplied-pmid 18760350?><pub-id pub-id-type="pmid">18760350</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dourmashkin</surname><given-names>RR</given-names></name><name><surname>Dunn</surname><given-names>G</given-names></name><name><surname>Castano</surname><given-names>V</given-names></name><name><surname>McCall</surname><given-names>SA</given-names></name></person-group><article-title>Evidence for an enterovirus as the cause of encephalitis lethargica</article-title><source>BMC Infect. Dis.</source><year>2012</year><volume>12</volume><fpage>136</fpage><?supplied-pmid 22715890?><pub-id pub-id-type="pmid">22715890</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>LA</given-names></name><name><surname>Vilensky</surname><given-names>JA</given-names></name></person-group><article-title>Encephalitis lethargica: 100 years after the epidemic</article-title><source>Brain</source><year>2017</year><volume>140</volume><fpage>2246</fpage><lpage>2251</lpage><?supplied-pmid 28899018?><pub-id pub-id-type="pmid">28899018</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limphaibool</surname><given-names>N</given-names></name><name><surname>Iwanowski</surname><given-names>P</given-names></name><name><surname>Holstad</surname><given-names>MJV</given-names></name><name><surname>Kobylarek</surname><given-names>D</given-names></name><name><surname>Kozubski</surname><given-names>W</given-names></name></person-group><article-title>Infectious etiologies of parkinsonism: pathomechanisms and clinical implications</article-title><source>Front. Neurol.</source><year>2019</year><volume>10</volume><fpage>652</fpage><?supplied-pmid 31275235?><pub-id pub-id-type="pmid">31275235</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>J</given-names></name><name><surname>Smeyne</surname><given-names>RJ</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name></person-group><article-title>Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries</article-title><source>Parkinsonism Relat. Disord.</source><year>2010</year><volume>16</volume><fpage>566</fpage><lpage>571</lpage><?supplied-pmid 20650672?><pub-id pub-id-type="pmid">20650672</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houser</surname><given-names>MC</given-names></name><name><surname>Tansey</surname><given-names>MG</given-names></name></person-group><article-title>The gut-brain axis: is intestinal inflammation a silent driver of Parkinson&#x02019;s disease pathogenesis?</article-title><source>NPJ Parkinson&#x02019;s Dis.</source><year>2017</year><volume>3</volume><fpage>3</fpage><pub-id pub-id-type="pmid">28649603</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike proteins</article-title><source>Annu. Rev. Virol.</source><year>2016</year><volume>3</volume><fpage>237</fpage><lpage>261</lpage><?supplied-pmid 27578435?><pub-id pub-id-type="pmid">27578435</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission</article-title><source>Sci. China Life Sci.</source><year>2020</year><volume>63</volume><fpage>457</fpage><lpage>460</lpage><?supplied-pmid 32009228?><pub-id pub-id-type="pmid">32009228</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280.e278</lpage><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrotta</surname><given-names>F</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Bianco</surname><given-names>A</given-names></name></person-group><article-title>Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?</article-title><source>Respir. Med.</source><year>2020</year><volume>168</volume><fpage>105996</fpage><?supplied-pmid 32364961?><pub-id pub-id-type="pmid">32364961</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. <italic>Cell</italic>. 10.1016/j.cell.2020.03.045 (2020).</mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Magrone, T., Magrone, M. &#x00026; Jirillo, E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug Target&#x02014;a perspective. <italic>Endocr. Metab. Immune Disord. Drug Targets.</italic>10.2174/1871530320666200427112902 (2020).</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><?supplied-pmid 7164637?><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Fantini, J., Di Scala, C., Chahinian, H. &#x00026; Yahi, N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. <italic>Int. J. Antimicrob. Agents.</italic>10.1016/j.ijantimicag.2020.105960 (2020).</mixed-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Milanetti, E., Miotto, M., Di Rienzo, L., Monti, M., Gosti, G. &#x00026; Ruocco, G. In-Silico evidence for two receptors based strategy of SARS-CoV-2. <italic>bioRxiv</italic>. Preprint at 10.1101/2020.03.24.006197 (2020).</mixed-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><etal/></person-group><article-title>Temporal dynamics in viral shedding and transmissibility of COVID-19</article-title><source>Nat. Med</source><year>2020</year><volume>26</volume><fpage>672</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0869-5</pub-id><?supplied-pmid 32296168?><pub-id pub-id-type="pmid">32296168</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>B</given-names></name></person-group><article-title>Bioinformatics studies on a function of the SARS-CoV-2 spike glycoprotein as the binding of host sialic acid glycans</article-title><source>Comput. Biol. Med.</source><year>2020</year><volume>122</volume><fpage>103849</fpage><?supplied-pmid 32658736?><pub-id pub-id-type="pmid">32658736</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasik</surname><given-names>BR</given-names></name><name><surname>Barnard</surname><given-names>KN</given-names></name><name><surname>Parrish</surname><given-names>CR</given-names></name></person-group><article-title>Effects of sialic acid modifications on virus binding and infection</article-title><source>Trends Microbiol.</source><year>2016</year><volume>24</volume><fpage>991</fpage><lpage>1001</lpage><?supplied-pmid 27491885?><pub-id pub-id-type="pmid">27491885</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><mixed-citation publication-type="other">Albright, B. H., Simon, K. E., Pillai, M., Devlin, G. W. &#x00026; Asokan, A. Modulation of sialic acid dependence influences the central nervous system transduction profile of adeno-associated viruses. <italic>J. Virol.</italic>10.1128/jvi.00332-19 (2019).</mixed-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffers</surname><given-names>SA</given-names></name><etal/></person-group><article-title>CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>15748</fpage><lpage>15753</lpage><?supplied-pmid 15496474?><pub-id pub-id-type="pmid">15496474</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways</article-title><source>J. Pathol.</source><year>2004</year><volume>203</volume><fpage>622</fpage><lpage>630</lpage><?supplied-pmid 15141376?><pub-id pub-id-type="pmid">15141376</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Multiple organ infection and the pathogenesis of SARS. J</article-title><source>Exp. Med.</source><year>2005</year><volume>202</volume><fpage>415</fpage><lpage>424</lpage></element-citation></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">Puelles, V. G. et al. Multiorgan and renal tropism of SARS-CoV-2. <italic>N. Engl. J. Med.</italic>10.1056/NEJMc2011400 (2020).</mixed-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19. <italic>Ann. Intern. Med.</italic>10.7326/M20-2003 (2020)</mixed-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Sepehrinezhad, A., Shahbazi, A. &#x00026; Negah, S. S. COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. <italic>J. Neurovirol.</italic>10.1007/s13365-020-00851-2 (2020).</mixed-citation></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="other">Natoli, S., Oliveira, V., Calabresi, P., Maia, L. F. &#x00026; Pisani, A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. <italic>Eur. J. Neurol.</italic>10.1111/ene.14277 (2020).</mixed-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netland</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Cassell</surname><given-names>M</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>7264</fpage><lpage>7275</lpage><?supplied-pmid 18495771?><pub-id pub-id-type="pmid">18495771</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>213</volume><fpage>712</fpage><lpage>722</lpage><?supplied-pmid 26486634?><pub-id pub-id-type="pmid">26486634</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YC</given-names></name><name><surname>Bai</surname><given-names>WZ</given-names></name><name><surname>Hirano</surname><given-names>N</given-names></name><name><surname>Hayashida</surname><given-names>T</given-names></name><name><surname>Hashikawa</surname><given-names>T</given-names></name></person-group><article-title>Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells</article-title><source>Virus Res.</source><year>2012</year><volume>163</volume><fpage>628</fpage><lpage>635</lpage><?supplied-pmid 22248641?><pub-id pub-id-type="pmid">22248641</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication</article-title><source>J. Comp. Neurol.</source><year>2013</year><volume>521</volume><fpage>203</fpage><lpage>212</lpage><?supplied-pmid 22700307?><pub-id pub-id-type="pmid">22700307</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andries</surname><given-names>K</given-names></name><name><surname>Pensaert</surname><given-names>MB</given-names></name></person-group><article-title>Immunofluorescence studies on the pathogenesis of hemagglutinating encephalomyelitis virus infection in pigs after oronasal inoculation</article-title><source>Am. J. Vet. Res.</source><year>1980</year><volume>41</volume><fpage>1372</fpage><lpage>1378</lpage><?supplied-pmid 6255837?><pub-id pub-id-type="pmid">6255837</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chasey</surname><given-names>D</given-names></name><name><surname>Alexander</surname><given-names>DJ</given-names></name></person-group><article-title>Morphogenesis of avian infectious bronchitis virus in primary chick kidney cells</article-title><source>Arch. Virol.</source><year>1976</year><volume>52</volume><fpage>101</fpage><lpage>111</lpage><?supplied-pmid 187144?><pub-id pub-id-type="pmid">187144</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Cytokine signaling modulates blood-brain barrier function</article-title><source>Curr. Pharm. Des.</source><year>2011</year><volume>17</volume><fpage>3729</fpage><lpage>3740</lpage><?supplied-pmid 21834767?><pub-id pub-id-type="pmid">21834767</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obermeier</surname><given-names>B</given-names></name><name><surname>Daneman</surname><given-names>R</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group><article-title>Development, maintenance and disruption of the blood-brain barrier</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1584</fpage><lpage>1596</lpage><?supplied-pmid 24309662?><pub-id pub-id-type="pmid">24309662</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muldoon</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Immunologic privilege in the central nervous system and the blood-brain barrier</article-title><source>J. Cereb. Blood. Flow. Metab.</source><year>2013</year><volume>33</volume><fpage>13</fpage><lpage>21</lpage><?supplied-pmid 23072749?><pub-id pub-id-type="pmid">23072749</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="other">Pilotto, A. et al. Steroid-responsive encephalitis in Covid-19 disease. <italic>Ann. Neurol</italic>. 10.1002/ana.25783 (2020).</mixed-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tipnis</surname><given-names>SR</given-names></name><etal/></person-group><article-title>A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>33238</fpage><lpage>33243</lpage><?supplied-pmid 10924499?><pub-id pub-id-type="pmid">10924499</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>HP</given-names></name><etal/></person-group><article-title>Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia</article-title><source>Am. J. Physiol. Lung Cell Mol. Physiol.</source><year>2009</year><volume>297</volume><fpage>L84</fpage><lpage>L96</lpage><?supplied-pmid 19411314?><pub-id pub-id-type="pmid">19411314</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F</given-names></name><etal/></person-group><article-title>Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><fpage>e85958</fpage><?supplied-pmid 24454948?><pub-id pub-id-type="pmid">24454948</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MY</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>XS</given-names></name></person-group><article-title>Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues</article-title><source>Infect. Dis. Poverty</source><year>2020</year><volume>9</volume><fpage>45</fpage><?supplied-pmid 32345362?><pub-id pub-id-type="pmid">32345362</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sluimer</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions</article-title><source>J. pathol.</source><year>2008</year><volume>215</volume><fpage>273</fpage><lpage>279</lpage><?supplied-pmid 18498093?><pub-id pub-id-type="pmid">18498093</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><etal/></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J. pathol.</source><year>2004</year><volume>203</volume><fpage>631</fpage><lpage>637</lpage><?supplied-pmid 15141377?><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doobay</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system</article-title><source>Am. J. Physiol. Regul. Integr. Comp. Physiol.</source><year>2007</year><volume>292</volume><fpage>R373</fpage><lpage>R381</lpage><?supplied-pmid 16946085?><pub-id pub-id-type="pmid">16946085</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowrisankar</surname><given-names>YV</given-names></name><name><surname>Clark</surname><given-names>MA</given-names></name></person-group><article-title>Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures</article-title><source>J. Neurochem.</source><year>2016</year><volume>138</volume><fpage>74</fpage><lpage>85</lpage><?supplied-pmid 27085714?><pub-id pub-id-type="pmid">27085714</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Lazartigues</surname><given-names>E</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2: central regulator for cardiovascular function</article-title><source>Curr. Hypertens. Rep.</source><year>2010</year><volume>12</volume><fpage>170</fpage><lpage>175</lpage><?supplied-pmid 20424953?><pub-id pub-id-type="pmid">20424953</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Sriramula</surname><given-names>S</given-names></name><name><surname>Chhabra</surname><given-names>KH</given-names></name><name><surname>Lazartigues</surname><given-names>E</given-names></name></person-group><article-title>Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension</article-title><source>Circ. res.</source><year>2013</year><volume>113</volume><fpage>1087</fpage><lpage>1096</lpage><?supplied-pmid 24014829?><pub-id pub-id-type="pmid">24014829</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Porretta</surname><given-names>C</given-names></name><name><surname>Nichols</surname><given-names>CD</given-names></name></person-group><article-title>Neurocytometry: flow cytometric sorting of specific neuronal populations from human and rodent brain</article-title><source>ACS Chem. Neurosci.</source><year>2017</year><volume>8</volume><fpage>356</fpage><lpage>367</lpage><?supplied-pmid 28135061?><pub-id pub-id-type="pmid">28135061</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells</article-title><source>Am. J. Physiol. Lung Cell Mol. Physiol.</source><year>2009</year><volume>297</volume><fpage>L631</fpage><lpage>L640</lpage><?supplied-pmid 19592460?><pub-id pub-id-type="pmid">19592460</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">Ziegler, C. G. K. et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. <italic>Cell.</italic>10.1016/j.cell.2020.04.035 (2020).</mixed-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Sriramula</surname><given-names>S</given-names></name><name><surname>Lazartigues</surname><given-names>E</given-names></name></person-group><article-title>Excessive glutamate stimulation impairs ACE2 activity through ADAM17-mediated shedding in cultured cortical neurons</article-title><source>Cell Mol. Neurobiol.</source><year>2018</year><volume>38</volume><fpage>1235</fpage><lpage>1243</lpage><?supplied-pmid 29766392?><pub-id pub-id-type="pmid">29766392</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><mixed-citation publication-type="other">Chen, R. et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. <italic>bioRxiv</italic>, 2020.2004.2007.030650. Preprint at 10.1101/2020.04.07.030650 (2020).</mixed-citation></ref><ref id="CR102"><label>102.</label><mixed-citation publication-type="other">Muus, C. et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. <italic>bioRxiv</italic>, 2020.2004.2019.049254. Preprint at 10.1101/2020.04.19.049254 (2020).</mixed-citation></ref><ref id="CR103"><label>103.</label><mixed-citation publication-type="other">Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. <italic>Nature.</italic>10.1038/s41586-020-2286-9 (2020).</mixed-citation></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">Lippi, A., Domingues, R., Setz, C., Outeiro, T. F. &#x00026; Krisko, A. SARS-CoV-2: at the crossroad between aging and neurodegeneration. <italic>Mov. Disord.</italic>10.1002/mds.28084 (2020).</mixed-citation></ref><ref id="CR105"><label>105.</label><mixed-citation publication-type="other">Ezzat, K. et al. The viral protein corona directs viral pathogenesis and amyloid aggregation. <italic>Nat. Commun</italic>. <bold>10</bold>, 2331 (2019).</mixed-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulisiak</surname><given-names>CT</given-names></name><name><surname>Mercado</surname><given-names>G</given-names></name><name><surname>Peelaerts</surname><given-names>W</given-names></name><name><surname>Brundin</surname><given-names>L</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name></person-group><article-title>Can infections trigger alpha-synucleinopathies?</article-title><source>Prog. Mol. Biol. Transl. Sci.</source><year>2019</year><volume>168</volume><fpage>299</fpage><lpage>322</lpage><?supplied-pmid 31699323?><pub-id pub-id-type="pmid">31699323</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massey</surname><given-names>AR</given-names></name><name><surname>Beckham</surname><given-names>JD</given-names></name></person-group><article-title>Alpha-synuclein, a novel viral restriction factor hiding in plain sight</article-title><source>DNA Cell. Biol.</source><year>2016</year><volume>35</volume><fpage>643</fpage><lpage>645</lpage><?supplied-pmid 27631132?><pub-id pub-id-type="pmid">27631132</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><mixed-citation publication-type="other">Lechien, J. R. et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. <italic>Eur. Arch. Otorhinolaryngol.</italic>10.1007/s00405-020-05965-1 (2020).</mixed-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinzel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Update of the MDS research criteria for prodromal Parkinson&#x02019;s disease</article-title><source>Mov. Disord.</source><year>2019</year><volume>34</volume><fpage>1464</fpage><lpage>1470</lpage><?supplied-pmid 31412427?><pub-id pub-id-type="pmid">31412427</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><mixed-citation publication-type="other">Kotecha, A. M., Corr&#x000ea;a, A. D. C., Fisher, K. M. &#x00026; Rushworth, J. V. Olfactory dysfunction as a global biomarker for sniffing out Alzheimer&#x02019;s disease: a meta-analysis. <italic>Biosensors.</italic>10.3390/bios8020041 (2018).</mixed-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barresi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Evaluation of olfactory dysfunction in neurodegenerative diseases</article-title><source>J. Neurol. Sci.</source><year>2012</year><volume>323</volume><fpage>16</fpage><lpage>24</lpage><?supplied-pmid 23010543?><pub-id pub-id-type="pmid">23010543</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">Abderrahmane, A. et al. Can the 2019 novel coronavirus cause Parkinson&#x02019;s disease? <italic>Mov. Disord.</italic>10.1002/mds.28118 (2020).</mixed-citation></ref><ref id="CR113"><label>113.</label><mixed-citation publication-type="other">Giacomelli, A. et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. <italic>Clin. Infect. Dis.</italic>10.1093/cid/ciaa330 (2020).</mixed-citation></ref><ref id="CR114"><label>114.</label><mixed-citation publication-type="other">Lovato, A. &#x00026; de Filippis, C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. <italic>Ear Nose Throat J.</italic>10.1177/0145561320920762 (2020).</mixed-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponsen</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Idiopathic hyposmia as a preclinical sign of Parkinson&#x02019;s disease</article-title><source>Ann. Neurol.</source><year>2004</year><volume>56</volume><fpage>173</fpage><lpage>181</lpage><?supplied-pmid 15293269?><pub-id pub-id-type="pmid">15293269</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddadi</surname><given-names>K</given-names></name><name><surname>Ghasemian</surname><given-names>R</given-names></name><name><surname>Shafizad</surname><given-names>M</given-names></name></person-group><article-title>Basal ganglia involvement and altered mental status: a unique neurological manifestation of coronavirus disease 2019</article-title><source>Cureus</source><year>2020</year><volume>12</volume><fpage>e7869</fpage><?supplied-pmid 32489724?><pub-id pub-id-type="pmid">32489724</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guttman</surname><given-names>M</given-names></name></person-group><article-title>Receptors in the basal ganglia</article-title><source>Can. J. Neurol. Sci.</source><year>1987</year><volume>14</volume><fpage>395</fpage><lpage>401</lpage><?supplied-pmid 2824009?><pub-id pub-id-type="pmid">2824009</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>DS</given-names></name></person-group><article-title>Dysautonomia in Parkinson disease</article-title><source>Compr. Physiol.</source><year>2014</year><volume>4</volume><fpage>805</fpage><lpage>826</lpage><?supplied-pmid 24715569?><pub-id pub-id-type="pmid">24715569</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><mixed-citation publication-type="other">M&#x000e9;ndez-Guerrero, A. et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. <italic>Neurology.</italic>10.1212/wnl.0000000000010282 (2020).</mixed-citation></ref><ref id="CR120"><label>120.</label><mixed-citation publication-type="other">Rodriguez-Perez, A. I. et al. Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra. <italic>Brain. Behav. Immun.</italic>10.1016/j.bbi.2019.12.011 (2019).</mixed-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joglar</surname><given-names>B</given-names></name><etal/></person-group><article-title>The inflammatory response in the MPTP model of Parkinson&#x02019;s disease is mediated by brain angiotensin: relevance to progression of the disease</article-title><source>J. Neurochem.</source><year>2009</year><volume>109</volume><fpage>656</fpage><lpage>669</lpage><?supplied-pmid 19245663?><pub-id pub-id-type="pmid">19245663</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garretti</surname><given-names>F</given-names></name><name><surname>Agalliu</surname><given-names>D</given-names></name><name><surname>Lindestam Arlehamn</surname><given-names>CS</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Sulzer</surname><given-names>D</given-names></name></person-group><article-title>Autoimmunity in Parkinson&#x02019;s Disease: the role of &#x003b1;-synuclein-specific T cells</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>303</fpage><?supplied-pmid 30858851?><pub-id pub-id-type="pmid">30858851</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindestam Arlehamn</surname><given-names>CS</given-names></name><name><surname>Garretti</surname><given-names>F</given-names></name><name><surname>Sulzer</surname><given-names>D</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><article-title>Roles for the adaptive immune system in Parkinson&#x02019;s and Alzheimer&#x02019;s diseases</article-title><source>Curr. Opin. Immunol.</source><year>2019</year><volume>59</volume><fpage>115</fpage><lpage>120</lpage><?supplied-pmid 31430650?><pub-id pub-id-type="pmid">31430650</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>ML</given-names></name><name><surname>Zecca</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name></person-group><article-title>Microglia-mediated neurotoxicity: uncovering the molecular mechanisms</article-title><source>Nat. Rev. Neurosci.</source><year>2007</year><volume>8</volume><fpage>57</fpage><lpage>69</lpage><?supplied-pmid 17180163?><pub-id pub-id-type="pmid">17180163</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>GP</given-names></name><etal/></person-group><article-title>T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease</article-title><source>Acta Neuropathol.</source><year>2020</year><volume>139</volume><fpage>855</fpage><lpage>874</lpage><?supplied-pmid 31993745?><pub-id pub-id-type="pmid">31993745</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodygin</surname><given-names>D</given-names></name><etal/></person-group><article-title>&#x003b2;-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration</article-title><source>Nature</source><year>2019</year><volume>566</volume><fpage>503</fpage><lpage>508</lpage><?supplied-pmid 30787438?><pub-id pub-id-type="pmid">30787438</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagne</surname><given-names>JJ</given-names></name><name><surname>Power</surname><given-names>MC</given-names></name></person-group><article-title>Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis</article-title><source>Neurology</source><year>2010</year><volume>74</volume><fpage>995</fpage><lpage>1002</lpage><?supplied-pmid 20308684?><pub-id pub-id-type="pmid">20308684</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>14063</fpage><lpage>14068</lpage><?supplied-pmid 19667183?><pub-id pub-id-type="pmid">19667183</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice</article-title><source>J. Neurosci.</source><year>2012</year><volume>32</volume><fpage>1545</fpage><lpage>1559</lpage><?supplied-pmid 22302798?><pub-id pub-id-type="pmid">22302798</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bantle</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Infection with mosquito-borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation</article-title><source>NPJ Parkinsons Dis.</source><year>2019</year><volume>5</volume><fpage>20</fpage><?supplied-pmid 31531390?><pub-id pub-id-type="pmid">31531390</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobasa</surname><given-names>D</given-names></name><etal/></person-group><article-title>Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus</article-title><source>Nature</source><year>2004</year><volume>431</volume><fpage>703</fpage><lpage>707</lpage><?supplied-pmid 15470432?><pub-id pub-id-type="pmid">15470432</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobasa</surname><given-names>D</given-names></name><etal/></person-group><article-title>Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>319</fpage><lpage>323</lpage><?supplied-pmid 17230189?><pub-id pub-id-type="pmid">17230189</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Systemic inflammatory response syndrome and prolonged hypoperfusion lesions in an infant with respiratory syncytial virus encephalopathy</article-title><source>J. Infect. Chemother.</source><year>2013</year><volume>19</volume><fpage>978</fpage><lpage>982</lpage><?supplied-pmid 23354937?><pub-id pub-id-type="pmid">23354937</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><mixed-citation publication-type="other">Sadasivan, S., Sharp, B., Schultz-Cherry, S. &#x00026; Smeyne, R. Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: experimental evidence for the multi-hit hypothesis. <italic>NPJ Parkinsons Dis</italic>. 10.1038/s41531-017-0019-z (2017).</mixed-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>WA</given-names></name><name><surname>Kastin</surname><given-names>AJ</given-names></name><name><surname>Broadwell</surname><given-names>RD</given-names></name></person-group><article-title>Passage of cytokines across the blood-brain barrier</article-title><source>Neuroimmunomodulation</source><year>1995</year><volume>2</volume><fpage>241</fpage><lpage>248</lpage><?supplied-pmid 8963753?><pub-id pub-id-type="pmid">8963753</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohanty</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prolonged proinflammatory cytokine production in monocytes modulated by interleukin 10 after influenza vaccination in older adults</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>211</volume><fpage>1174</fpage><lpage>1184</lpage><?supplied-pmid 25367297?><pub-id pub-id-type="pmid">25367297</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>NL</given-names></name><etal/></person-group><article-title>Oseltamivir prophylaxis reduces inflammation and facilitates establishment of cross-strain protective T cell memory to influenza viruses</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0129768</fpage><?supplied-pmid 26086392?><pub-id pub-id-type="pmid">26086392</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Endothelial cell infection and endotheliitis in COVID-19</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1417</fpage><lpage>1418</lpage><?supplied-pmid 32325026?><pub-id pub-id-type="pmid">32325026</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>LM</given-names></name><name><surname>Duval</surname><given-names>EJ</given-names></name><name><surname>Stroberg</surname><given-names>E</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 autopsies, Oklahoma, USA</article-title><source>Am. J. Clin. Pathol.</source><year>2020</year><volume>153</volume><fpage>725</fpage><lpage>733</lpage><?supplied-pmid 32275742?><pub-id pub-id-type="pmid">32275742</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir. Med.</source><year>2020</year><volume>8</volume><fpage>420</fpage><lpage>422</lpage><?supplied-pmid 7164771?><pub-id pub-id-type="pmid">32085846</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer</article-title><source>J. Thorac. Oncol.</source><year>2020</year><volume>15</volume><fpage>700</fpage><lpage>704</lpage><?supplied-pmid 7128866?><pub-id pub-id-type="pmid">32114094</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><mixed-citation publication-type="other">Adachi, T. et al. Clinicopathologic and immunohistochemical findings from autopsy of patient with COVID-19, Japan. Emerg. <italic>Infect. Dis.</italic>10.3201/eid2609.201353 (2020).</mixed-citation></ref><ref id="CR143"><label>143.</label><mixed-citation publication-type="other">Menter, T. et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. <italic>Histopathology.</italic>10.1111/his.14134 (2020).</mixed-citation></ref><ref id="CR144"><label>144.</label><mixed-citation publication-type="other">Cilia, R. et al. Effects of COVID-19 on Parkinson&#x02019;s disease clinical features: a community-based case-control study. <italic>Mov. Disord.</italic>10.1002/mds.28170 (2020).</mixed-citation></ref><ref id="CR145"><label>145.</label><mixed-citation publication-type="other">Fasano, A. et al. COVID-19 in Parkinson&#x02019;s disease patients living in Lombardy, Italy. <italic>Mov. Disord.</italic>10.1002/mds.28176 (2020).</mixed-citation></ref><ref id="CR146"><label>146.</label><mixed-citation publication-type="other">Papa, S. M. et al. Impact of the COVID-19 pandemic on Parkinson&#x02019;s disease and movement disorders. <italic>Mov. Disord.</italic>10.1002/mds.28067 (2020).</mixed-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoessl</surname><given-names>AJ</given-names></name><name><surname>Bhatia</surname><given-names>KP</given-names></name><name><surname>Merello</surname><given-names>M</given-names></name></person-group><article-title>Movement disorders in the world of COVID-19</article-title><source>Mov. Disord. Clin. Pract.</source><year>2020</year><volume>7</volume><fpage>355</fpage><lpage>356</lpage><?supplied-pmid 32373650?><pub-id pub-id-type="pmid">32373650</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><mixed-citation publication-type="other">Bhidayasiri, R., Virameteekul, S., Kim, J. M., Pal, P. K. &#x00026; Chung, S. J. COVID-19: an early review of its global impact and considerations for Parkinson&#x02019;s Disease Patient Care. <italic>J. Mov. Disord.</italic>10.14802/jmd.20042 (2020).</mixed-citation></ref><ref id="CR149"><label>149.</label><mixed-citation publication-type="other">Schirinzi, T. et al. Self-reported needs of patients with Parkinson&#x02019;s disease during COVID-19 emergency in Italy. <italic>Neurol. Sci.</italic>10.1007/s10072-020-04442-1 (2020).</mixed-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tipton</surname><given-names>PW</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name></person-group><article-title>What can Parkinson&#x02019;s disease teach us about COVID-19?</article-title><source>Neurol. Neurochir. Pol.</source><year>2020</year><volume>54</volume><fpage>204</fpage><lpage>206</lpage><?supplied-pmid 32323862?><pub-id pub-id-type="pmid">32323862</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>A</given-names></name><etal/></person-group><article-title>Management of advanced therapies in Parkinson&#x02019;s disease patients in times of humanitarian crisis: the COVID-19 experience</article-title><source>Mov. Disord. Clin. Pract.</source><year>2020</year><volume>7</volume><fpage>361</fpage><lpage>372</lpage><?supplied-pmid 32373652?><pub-id pub-id-type="pmid">32373652</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baille</surname><given-names>G</given-names></name><etal/></person-group><article-title>Dyspnea: an underestimated symptom in Parkinson&#x02019;s disease</article-title><source>Parkinsonism Relat. Disord.</source><year>2019</year><volume>60</volume><fpage>162</fpage><lpage>166</lpage><?supplied-pmid 30224267?><pub-id pub-id-type="pmid">30224267</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><mixed-citation publication-type="other">Prasad, S. et al. Parkinson&#x02019;s Disease and COVID-19: perceptions and implications in patients and caregivers. <italic>Mov. Disord.</italic>10.1002/mds.28088 (2020).</mixed-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roland</surname><given-names>KP</given-names></name><name><surname>Cornett</surname><given-names>KM</given-names></name><name><surname>Theou</surname><given-names>O</given-names></name><name><surname>Jakobi</surname><given-names>JM</given-names></name><name><surname>Jones</surname><given-names>GR</given-names></name></person-group><article-title>Concurrence of Frailty and Parkinson&#x02019;s disease</article-title><source>J. Frailty Aging</source><year>2012</year><volume>1</volume><fpage>123</fpage><lpage>127</lpage><?supplied-pmid 27093200?><pub-id pub-id-type="pmid">27093200</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torsney</surname><given-names>KM</given-names></name><name><surname>Forsyth</surname><given-names>D</given-names></name></person-group><article-title>Respiratory dysfunction in Parkinson&#x02019;s disease</article-title><source>J. R. Coll. Physicians Edinb.</source><year>2017</year><volume>47</volume><fpage>35</fpage><lpage>39</lpage><?supplied-pmid 28569280?><pub-id pub-id-type="pmid">28569280</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCray</surname><given-names>PB</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>813</fpage><lpage>821</lpage><?supplied-pmid 17079315?><pub-id pub-id-type="pmid">17079315</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>K</given-names></name><etal/></person-group><article-title>The vagus nerve is one route of transneural invasion for intranasally inoculated influenza a virus in mice</article-title><source>Vet. Pathol.</source><year>2004</year><volume>41</volume><fpage>101</fpage><lpage>107</lpage><?supplied-pmid 15017022?><pub-id pub-id-type="pmid">15017022</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>JF</given-names></name></person-group><article-title>Epstein-Barr virus and the chronic fatigue syndrome: a short review</article-title><source>Microbiol. Sci.</source><year>1988</year><volume>5</volume><fpage>366</fpage><lpage>369</lpage><?supplied-pmid 2856301?><pub-id pub-id-type="pmid">2856301</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazcano-Ocampo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Identifying and responding to fatigue and apathy in Parkinson&#x02019;s disease: a review of current practice</article-title><source>Expert Rev. Neurother.</source><year>2020</year><volume>20</volume><fpage>477</fpage><lpage>495</lpage><?supplied-pmid 32290717?><pub-id pub-id-type="pmid">32290717</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><mixed-citation publication-type="other">Smieszek, S. P., Przychodzen, B. P. &#x00026; Polymeropoulos, M. H. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. <italic>Int. J. Antimicrob. Agents</italic>. 10.1016/j.ijantimicag.2020.106004 (2020).</mixed-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of fatigue in Parkinson&#x02019;s disease: the fatigue impact scale for daily use (D-FIS)</article-title><source>Qual. Life Res.</source><year>2006</year><volume>15</volume><fpage>597</fpage><lpage>606</lpage><?supplied-pmid 16688493?><pub-id pub-id-type="pmid">16688493</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helmich</surname><given-names>RC</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name></person-group><article-title>The Impact of the COVID-19 pandemic on Parkinson&#x02019;s disease: hidden sorrows and emerging opportunities</article-title><source>J. Parkinsons Dis.</source><year>2020</year><volume>10</volume><fpage>351</fpage><lpage>354</lpage><?supplied-pmid 32250324?><pub-id pub-id-type="pmid">32250324</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><mixed-citation publication-type="other">van Wamelen, D. J. Wan, Y. M., Chaudhuri, K. R. &#x00026; Jenner, P. Stress and cortisol in Parkinson&#x02019;s disease. <italic>Int. Rev. Neurobiol</italic>. 10.1016/bs.irn.2020.01.005 (2020).</mixed-citation></ref></ref-list></back></article>